Chimeric Therapeutics Limited

T Cell Derived Autologous Therapies

Team

About Cell Therapy

Pipeline

NK Cell Derived Allogeneic Therapies

Science

Governance

Announcements

Updates

New investors

Investor Hub

Home

About Us

DM Sans

Click here to visit our dedicated Entitlement Offer (NREO) page for all the information you need to participate. 

T cells are part of our adaptive immune system – the system that tailors the body’s response to specific pathogens. Rather than generically attack any antigens, T cells circulate until they encounter a specific antigen, playing a critical part in immunity to foreign substances.

Benefits of T Cell derived therapies may include:

Primed to target and attack specific antigens

Responsible for immune mediated cell death

Demonstrated in vivo expansion / proliferation potential

CHM 1101 (CLTX CAR T) is an optimised first-in-class CAR T cell therapy that uniquely utilises Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting domain.

CHM 1101 has been shown to more specifically and broadly target GBM cells than other immunotherapy targets like HER2, EGFR and IL13, through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2)

CHM 1101 demonstrated excellent preclinical safety with no off tumour recognition of normal human or murine cells or tissues in preclinical models, consistent with the documented safety of administering CLTX containing agents in humans

CHM 1101 demonstrated potent anti-tumour activity in vivo with significantly improved survival in mice

CHM 1101 is currently in clinical trials in patients with recurrent or progressive glioblastoma.

Based upon evidence of CLTX binding in other solid tumours, preclinical studies are currently ongoing to determine the potential of CHM 1101 in solid tumours such as melanoma, colorectal cancer and prostate cancer.

CHM 2101 (CDH17 CAR T) is an optimised 3rd generation CAR T cell therapy that is the first to target CDH17.

CHM 2101 was optimised over a decade of development to address the high unmet medical needs of patients with neuroendocrine tumours

A potent anti cancer antibody that is optimally and specifically bound to neuroendocrine tumour cells was developed and through robust target validation, CDH17 was identified as the antigen target

The CDH17 CAR T was optimised as a 3rd generation construct with both CD28 and 41BB costimulatory domains

CHM 2101 preclinical evidence have demonstrated a unique potency for solid tumours with complete eradication of tumour cells with no relapse

Preclinical studies also demonstrated no toxicity to normal tissues.

Although CDH17 is known to be expressed on normal epithelial cells, the CDH17 CAR T cells only infiltrated the tumour cells, sparing the normal cells, even when they expressed CDH17.

In normal cells, CDH17 is inaccessible as it is hidden beneath tight junctions that reinforce the barriers of normal cells while in cancer, CDH17 upregulation results in exposure of the CDH17 on the cancer cells allowing the CAR T to detect and bind to it.

With the evidence of high CDH 17 expression in solid tumours, CHM 2101 is being studied in neuroendocrine tumours as well as in gastrointestinal (GI) cancers such as colorectal, pancreatic and gastric cancer.